Close

Cara Therapeutics (CARA) Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA Injection in Hemodialysis Patients with CKD-aP

January 31, 2018 7:11 AM EST Send to a Friend
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login